| Summary: | 碩士 === 高雄醫學大學 === 醫學研究所 === 98 === Leukemia is one major kind of malignancy with high mortality
worldwide. The current chemical agents for leukemia treatment are usually with greater side effects, so the development of new therapeutic agent is critical. K-562, a chronic myeloid leukemia (CML) cell line, is a common model to study anti-proliferation drug of leukemia. Tellimagrandin II (TGII) is one kind of plant polyphenol, extracted from the shell of Trapa hispinosa. In the previous study, polyphenols were shown to be powerful anti-carcinogenic properties, including green tea, red wine. In this study, we aimed to investigate the effects of TG II on leukemic cells to evaluate the potential of TGII as therapeutic agent for leukemia.
In current study, we investigated the potential role of TG II on the anti-leukemia. The cell viability was measured by WST-1 assay. The IC50s, determined after 24 and 48 hours incubation, were 57.01 and 48.11 μM, respectively. Furthermore, using TUNEL assay to detect the DNA fragmentation, we found TGII induced K562 cell apoptosis at 50μM.. On the cell cycle regulation, increasing of sub-G1 fraction and G2/M phase arrest of K562 by TGII was found. We also found the accumulation of intracellular reactive oxygen species under the indicated TGII concentration. Taken together, we predicted that TGII induced mitochondrial mediated apoptosis in K-562 cells and arrested the cell cycle in G2/M phase.
|
|---|
